Background-Warfarin therapy is often withheld from elderly patients who fall or otherwise experience injury because of concerns regarding the long-term risk of hemorrhage in these individuals. We studied whether stopping warfarin after trauma is associated with a higher risk of subsequent adverse cardiovascular events. Methods and Results-We conducted a retrospective, population-based, cohort study using linked administrative databases in the province of Ontario, Canada for the years 1992 to 2001. A total of 8450 elderly patients (age Ͼ65 years) who survived an incident of major trauma and were receiving warfarin before injury were followed up for a mean of 3.3 years. During the 6-month interval after trauma, 1827 (22%) patients discontinued warfarin, whereas 6623 (78%) patients continued warfarin. Warfarin cessation was not associated with an increased risk of subsequent stroke (hazard ratio [HR] 0.99, 95% CI 0.82 to 1.21) or myocardial infarction (HR 0.94, 95% CI 0.74 to 1.20) but was associated with a lower risk of major hemorrhage (HR 0.69, 95% CI 0.54 to 0.88) and a higher risk of venous thromboembolism (HR 1.59, 95% CI 1.07 to 2.36). Adjustment for baseline demographics, stroke risk factors, other comorbidities, and characteristics of the trauma did not materially change these findings. On-treatment analyses yielded similar results. Conclusions-Cessation of warfarin in elderly patients after major trauma was not associated with an increased risk of arterial thrombotic events but was associated with a significantly increased risk of venous thromboembolism.
W arfarin is an oral anticoagulant widely used for preventing thromboembolism in patients with atrial fibrillation, prosthetic heart valves, and venous thrombosis. 1 Despite its proven efficacy for preventing strokes, warfarin is frequently withheld from elderly patients because of concerns about major hemorrhage. [2] [3] [4] [5] [6] [7] [8] [9] Factors that increase the risk of bleeding are often prevalent in the elderly, including prior gastrointestinal hemorrhage, erratic compliance, and a tendency to fall. 10, 11 The tradeoff between benefits and risks of warfarin leads to considerable uncertainty about the decision to prescribe this therapy to older patients in the community. 12, 13 In one study of physician attitudes regarding warfarin for stroke prevention, for example, the most commonly cited contraindication was an increased risk of falls (reported by 71% of respondents). 14 Patients who sustain major trauma while receiving warfarin may bleed more seriously from their injuries, particularly when craniocerebral trauma occurs. [15] [16] [17] [18] However, the medical literature offers remarkably little evidence to guide physicians about resumption of long-term oral anticoagulation in patients who survive major trauma. The potential protection from stroke and other thrombotic events favors the reinstitution of long-term anticoagulation. Conversely, the occurrence of trauma may be a marker of poor functional status, comorbidity, or unreliable patient behavior that may seriously compromise the benefits of long-term warfarin therapy. 19 We hypothesized that elderly patients who discontinue warfarin after major trauma face an increased risk of adverse cardiovascular events. Specifically, our theory was that major trauma does not reverse the rationale for resuming warfarin. By monitoring a population-based cohort of elderly patients who sustained major trauma while coincidentally receiving warfarin, we assessed the long-term effects associated with discontinuation of warfarin after trauma. We did not examine the short-term (Ͻ6 months) benefits and risks of oral anticoagulation after trauma for prophylaxis or other indications.
Methods

Setting and Design
We conducted a population-based, retrospective, cohort study by linking multiple administrative healthcare databases over a 9-year period (January 1, 1992, to January 1, 2001) in the province of Ontario. Throughout the study, Ontario was Canada's most populous province, with Ϸ12 million residents, of whom 1.5 million were aged 65 years or older. Elderly patients in Ontario had universal access to hospital care, physicians' services, and prescription drug coverage. In addition, healthcare records could be analyzed with encrypted health card numbers to track individual patients over time. 20 Ethical approval for the study was obtained from the Sunnybrook and Women's College Health Sciences Centre Research Ethics Board.
Data Sources
We used 4 large databases: the Ontario Drug Benefit database, which records prescription medications dispensed to elderly patients in Ontario; the Canadian Institute for Health Information (CIHI) discharge abstract database, which records hospital admissions, including detailed diagnostic and procedural information; the Ontario Health Insurance Plan database, which provides information on physician claims for inpatient and outpatient services; and the Ontario Registered Persons database, which contains vital statistics on all residents in the province. These 4 databases have been used extensively to study population-based health outcomes. 21, 22 
Patients
Patients were included if they were 66 years of age or older at the time of major trauma, defined as a hospitalization for which trauma was the most responsible diagnosis. We used International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) E codes 800 through 999 to define and categorize all subtypes of trauma. We excluded patients whose admission was primarily related to late effects of trauma (E code 929), complications of medical procedures (E codes 930 to 949), or poisonings (E codes 849 to 879). We focused on patients who had recently received warfarin, defined as at least 1 prescription for warfarin within 6 months before the trauma. We excluded those patients who died in the hospital or who did not survive for at least 6 months after discharge to remove deaths that might be linked to the incident trauma and recovery.
Comorbidities
The frequency of major stroke risk factors and other comorbid diseases was determined by analysis of inpatient and outpatient databases before trauma. In accord with past research, the 7 prespecified stroke risk factors were atrial fibrillation, a prosthetic heart valve, diabetes mellitus, hypertension, heart failure, previous stroke or transient ischemic attack, and coronary artery disease. 23 Additional prespecified comorbidities were a history of falls, alcoholism, dementia, previous major hemorrhage, malignancy, and renal insufficiency. The Charlson Comorbidity Index score was used to quantify overall comorbidity. 24 Two additional generic indices of comorbidity were provided by the number of hospital admissions in the preceding 3 years and the number of distinct medications prescribed in the past year. 25
Outcomes
The primary end point was the first occurrence of ischemic stroke, defined as admission to hospital with ischemic stroke as the most responsible diagnosis (ICD-9-CM codes 433, 434, and 436). The accuracy rate of coding for stroke in the CIHI database exceeds 90%. 23, 26 The 4 secondary end points examined were major hemorrhage, acute myocardial infarction, venous thromboembolism, and death. Major hemorrhage was defined according to an admission with the most responsible diagnosis of hemorrhage or for a procedure to repair hemorrhage (appendix A for ICD-9-CM diagnosis and procedure codes for hemorrhage). Myocardial infarction was defined as an admission with the most responsible diagnosis of myocardial infarction (ICD-9-CM 410). These diagnosis codes have a positive predictive value of 90% to 96%. 27, 28 Venous thromboembolism was defined as an admission with a most responsible diagnosis of pulmonary embolism (ICD-9-CM 415.1) or deep vein thrombosis (ICD-9-CM 325, 437.6, 451 to 453). These diagnosis codes have a sensitivity of 97% and a specificity of 90% for true thromboembolic disease. 29 All-cause mortality was obtained from the Registered Persons database.
Subgroups
Predefined subgroups were identified to compare event rates in 9 settings: a history of atrial fibrillation; history of stroke or transient ischemic attack; history of diabetes mellitus; history of hypertension; history of congestive heart failure; history of coronary artery disease; history of malignancy; absence of head injury on trauma; and trauma resulting from a fall. The intent of these subgroup analyses was to examine warfarin therapy in distinct patient populations, particularly in those settings established by the literature as representing elevated risk of major vascular events.
Statistical Analysis
We defined the period of observation as beginning 6 months after discharge. Follow-up ended at the time of a primary event, death, or the end of the study if the patient course was uneventful (March 31, 2002) . The primary analysis compared patients who discontinued warfarin by 6 months after discharge with patients who continued taking warfarin. Crude differences between the 2 groups in the risk of outcomes were calculated as hazard ratios (HRs) with Cox regression models and subsequently adjusted for demographic factors, stroke risk factors, and other covariates (comorbidities and characteristics of the trauma).
We also conducted an on-treatment analysis by checking for warfarin claims in the prescription database within 6 months immediately before the occurrence of an outcome. In the treated group, we regarded on-treatment outcomes as those for which at least 1 claim for warfarin was made within 6 months before the event. Similarly, for those who discontinued warfarin, we retained only outcomes for which no claim for warfarin was made within the 6-month preevent interval. The intent of the on-treatment analysis was to examine the consistency of findings with a more precise measure of patient compliance.
Results
During the 9-year study period, 11 139 patients receiving warfarin sustained trauma and were treated at 252 hospitals in Ontario. Of these, 1284 (11%) died in the hospital, and an additional 1405 (13%) died within 6 months of discharge; 61 of these deaths were due to stroke. Of the 8450 long-term survivors, 6623 (78%) resumed the use of warfarin during the 6-month period after discharge, whereas 1827 (22%) did not resume warfarin (Table) . Collectively, this cohort provided 27 530 person-years of follow-up after major trauma (mean duration of follow-up, 3.3 years). The majority (82%) of trauma episodes were due to falls.
Patients who discontinued using long-term warfarin after trauma were similar to those who continued its use in basic demographics, stroke risk factors, and other comorbidities. The major exception was that atrial fibrillation was somewhat less common in those who discontinued the use of warfarin. The subtypes of trauma were fairly evenly distributed between the 2 groups. A past history of major hemorrhage was equally common in both groups.
A total of 592 patients sustained an ischemic stroke during follow-up, equivalent to a rate of 2.2% per year. We observed no difference in the risk of stroke in the patients who discontinued warfarin compared with those who continued its use, even after adjustment for demographic factors, stroke risk factors, and other covariates (Figures 1 and 2) . Although the rate of stroke varied substantially across the different subgroups, in no subgroup was warfarin cessation associated with an increased risk of stroke (including patients with atrial fibrillation or those with prior cerebrovascular disease). The on-treatment analysis continued to show no evidence of an association between warfarin cessation and an increased risk of ischemic stroke.
A total of 399 patients sustained an acute myocardial infarction during follow-up, equivalent to an annual incidence of 1.5%. As with stroke, we observed no apparent relation between warfarin discontinuation and the subsequent long-term risk of myocardial infarction (Figure 3 ). This lack of association was apparent in both the crude and adjusted analyses, all subgroups, and the on-treatment analysis. There were 4203 deaths in the trauma cohort, with an overall mortality rate of Ϸ16% per year. We found a slight but statistically significant increase in mortality in those who discontinued using warfarin (HR 1.09, 95% CI 1.02 to 1.18), a finding which was no longer significant after adjustment for covariates (HR 1.05, 95% CI 0.98 to 1.13).
The long-term risk of major hemorrhage for trauma patients who discontinued warfarin use was 1.3% annually, which was significantly lower than the rate for trauma patients who resumed using warfarin (1.9%; Pϭ0.0025 for difference). In the unadjusted model, the risk of major hemorrhage was increased by 45% in those who continued using warfarin, an association that persisted after adjustment for age, sex, stroke risk factors, comorbidities, and trauma characteristics (Figure 4) . The increased risk of hemorrhage for trauma patients who continued to use warfarin was consistent across most major subgroups, accentuated in patients with a previous history of stroke or transient ischemic attack, and further strengthened in the on-treatment analysis. There were 115 episodes of venous thromboembolism over the course of follow-up, equivalent to a rate of 0.4% annually. Discontinuation of warfarin use was associated with a significant increase in the risk of venous thromboembolism ( Figure 5 ). This finding was strengthened in the on-treatment analysis and was consistent across most subgroups. Overall, the increase in venous thromboembolism primarily reflected a substantial increase in hospitalizations for deep vein thrombosis (HR 1.94, 95% CI 1.18 to 3.18), with no significant increase in pulmonary embolism (HR 1.01, 95% CI 0.52 to 1.97).
Characteristics of Patients Prescribed Warfarin Before Major Trauma
A number of risk factors for the combined outcome of death or stroke were corroborated in the anticipated manner in the full cohort. As expected, age was the strongest predictor and was associated with a 44% increase in risk for each decade increase in age (95% CI 38% to 51%). Similarly, male gender (HR 1.21, 95% CI 1.15 to 1.25), past stroke or transient ischemic attack (HR 1.12, 95% CI 1.06 to 1.19), renal insufficiency (HR 1.11, 95% CI 1.03 to 1.19), and dementia (HR 1.19, 95% CI 1.10 to 1.29) were further independent risk factors for the combined end point. Similar results were noted in the atrial fibrillation subgroup.
Discussion
Multiple studies support the efficacy and safety of warfarin for preventing stroke, myocardial infarction, and venous thromboembolism. 30 -32 In particular, warfarin reduces the risk of ischemic stroke by approximately two thirds in patients with atrial fibrillation. 33 In many settings, the moderately raised incidence of bleeding related to warfarin is greatly outweighed by the benefits in preventing stroke, disability, and death 34, 35 ; however, controversy surrounds the risk-benefit ratio of warfarin use after trauma, and we found that 1 in 5 patients discontinued their use of warfarin after hospitalization for major trauma. Moreover, those patients who discontinued long-term warfarin experienced fewer adverse events than were observed in the placebo groups of prior randomized trials.
The largest limitation of the present study is that the lack of random allocation to warfarin therapy raises the possibility of selection bias; furthermore, poor compliance might slant the analysis against warfarin. However, 4 additional findings suggest that hidden confounding is unlikely to explain the results. First, we made adjustments for many factors that are known to be prognostically important. These adjustments did not affect the results of our analysis. Second, analyses of specific high-risk subgroups of patients were consistent with the overall cohort. Third, bias due to poor compliance would not explain why all the main findings were replicated in the on-treatment analyses. Finally, the significantly increased risk of hemorrhage in those who continued the use of warfarin suggests at least some degree of anticoagulation in these patients, thus arguing against major noncompliance.
One possible explanation for our findings is behavioral. Elderly patients who are prone to trauma are more likely to have comorbidities (such as dementia) and neurobehavioral attributes (such as poor attention) that may predispose to reduced efficacy with warfarin. 36 -39 Such characteristics could result in poor compliance with warfarin therapy and potential lapses in followup, monitoring, and dose adjustment. 40 -42 These patients would thus be predisposed to subtherapeutic (stroke-promoting) and supratherapeutic (hemorrhage-promoting) levels of anticoagulation. Consistent with this explanation, many patients in the present study cohort had a history of dementia, polypharmacy, malignancy, and other comorbid conditions that may compromise the efficacy and safety of warfarin.
A second possible explanation is that patients with severe cerebrovascular disease might not survive major trauma or its sequelae. [43] [44] [45] This might also explain why the annual incidence of ischemic stroke observed in the present study cohort was lower than expected from population studies. Hence, major trauma may have depleted the patients who were most prone to strokes (the same subset of patients most likely to benefit from warfarin). 46, 47 Because the observation period of the present study began at 6 months after trauma, our results do not address whether warfarin is beneficial in the early posttrauma period. Intriguingly, however, we found a significant increase in the long-term risk of venous thromboembolism in trauma patients who discontinued warfarin. Although randomized controlled trials have shown significant reductions in the risk of venous thrombosis with early anticoagulation after trauma, this is the first study, to the best of our knowledge, that suggests long-term warfarin use may also be protective.
The literature on the safety of resuming warfarin after trauma is remarkably limited. A recent decision analysis concluded that a patient would need to fall Ϸ300 times per year to outweigh the benefits of long-term warfarin use for stroke prevention 35 ; however, that decision analysis was based on randomized controlled trials that generally excluded trauma patients. Moreover, the presence of comorbidities that increase the risk of hemorrhage and cluster with the risk of trauma were not considered in the analysis. A recent cohort study of unselected trauma patients found substantially lower rates of discharge to the community in patients using warfarin at the time of trauma. 48 Moreover, warfarin users had significantly worse functional outcomes than nonusers of warfarin, particularly those who sustained head injury at the time of trauma.
We found that discontinuation of long-term warfarin use after major trauma was not associated with an increased risk of stroke or myocardial infarction but was associated with a significant increase in the risk of venous thromboembolism. Further research is necessary to replicate our work. In the meantime, physicians who prescribe long-term warfarin to patients with a history of trauma should carefully weigh the competing risks of hemorrhage and venous thromboembolism. Figure 5 . HRs represent ratio of risk of venous thromboembolism for warfarin desisters vs warfarin persisters as reference group. Ⅲ indicates unadjusted analyses; ⅜, analyses adjusted for demographic factors, stroke risk factors, comorbidities, and characteristics of incident trauma. Results for full cohort appear at top; results based on treatment actually received appear at bottom.
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